Biovica Q1 2023/24: Early launch progress - Redeye

Biovica delivers early sales progress with SEK 1.7m in Q1 sales. The OPEX is in line with our expectations and the cash position is slightly below at SEK 76m. At this stage Biovica's sales relates to research use and the expanding pharma interest in DiviTum. Biovica has signed three commercial agreements during Q1 but has not yet completed any of the direct contract with hospital chains (or Hospital networks) which in our view is a delay. Biovica confirms that it is in the late stage of signing several direct contracts with US hospital chains which is our view is the next important milestone for Biovica. The PLA code is a major achievement and the code is active as from 1 October and the next step is to establish a related price which could be in place by the end of this calendar year. We do not expect any major share price reaction as as a result of the Q1 announcement.

Länk till analysen i sin helhet: https://www.redeye.se/research/941704/biovica-q1-2023-24-early-launch-progress?utm_source=finwire&utm_medium=RSS